How many mutant p53 molecules are needed to inactivate a tetramer?

Area of Science:

• Molecular Biology
• Cancer Genetics

Background:

• The tumor suppressor p53 protein is a transcription factor crucial for preventing cancer.
• Most p53 mutations are missense mutations affecting DNA binding.
• p53-related proteins p63 and p73 have variants lacking the N-terminal transactivation domain (NDelta).

Purpose of the Study:

• To investigate the dominant-negative effects of p53 mutants on wild-type p53 function.
• To determine the number of mutant subunits required to inactivate a p53 tetramer.
• To compare the inhibitory potential of DNA-binding defective mutants versus N-terminally truncated variants.

Main Methods:

• Theoretical predictions of mutant p53 monomer requirements for tetramer inactivation.
• Experimental validation of theoretical predictions using specific p53 mutants (R249S, R273H).
• Assessment of p53NDelta and related NDelta variants' inhibitory capacity.

Main Results:

• DNA-binding defective p53 mutants (R249S, R273H) are poor inhibitors, requiring at least three mutants to inactivate a tetramer.
• p53NDelta is a potent inhibitor, with one NDelta subunit per tetramer abolishing transcriptional activity.
• NDelta variants of p63 and p73 also potently inhibit p53 family members, independent of DNA binding.

Conclusions:

• The mechanism of dominant-negative inhibition by p53 mutants varies significantly.
• N-terminally truncated p53 variants (p53NDelta) are much more potent inhibitors than DNA-binding defective mutants.
• These findings impact understanding of tumorigenesis involving p53 mutations and truncated isoforms.